Fig 1.
(A) AGV (New World Medical, Inc., USA, FP8). (B) The 5-Fu-PCL sustained-release film was fixed on the AGV with a 10–0 suture.
Fig 2.
Drug-release profile of the 5-Fu-PCL film (n = 3, mean ± SD).
Fig 3.
Slit-lamp microscope observations.
(A) Diffuse filtering bleb in group A. (B) Flattened bleb on the AS-OCT image in groups B and C.
Fig 4.
(A) AS-OCT reveals the central depth of the anterior chamber. (B) Drainage tube in the anterior chamber without occlusion. (C) Diffuse filtering bleb in group A. (D) Flattened bleb on the AS-OCT image in groups B and C.
Fig 5.
IOP after AGV implantation (mean ± SD, n = 6).
Fig 6.
Central depth of the anterior chamber after AGV implantation.
“★” P < 0.05 between group A and groups B and C.
Fig 7.
Bleb in a rabbit eye after implantation of AGV and 5-Fu-PCL sustained-release film, as indicated by the arrows.
Fig 8.
Hematoxylin-eosin staining of a bleb after AGV implantation.
(A) Group A. (B) Group B. (C) Group C. Original magnification ×10.
Fig 9.
Effect of the 5-Fu-PCL sustained-release film on fibrous capsule thickness in various regions of the bleb wall.
Values are presented as the mean ± standard error of the mean (SEM). “★” P < 0.05 between group A and groups B and C.